All the Therapeutic System Drugs
Domapine Agonist. Cabergoline 0.5 mg. TABS: 2, 8. Take with meals. Dose: See
lit.
Tmt. dysfuncts., assoc. with
hyperprolactinem., incl. amenorrh.,
oligomenorrh., anovulat., galactorrh. In
pts. with prolactin-secret. pituitary
adenomas (micro/macro) idiopath.
hyperprolactinem., empty sella syndr.
with assoc. hyperprolactinem.
C/I: Hypersens., any ergot alkaloid,
uncontrolled hypertens.
Domapine Agonist. Cabergoline 0.5 mg. TABS: 8. 1 tab. wkly. in 1 or 2 doses. If necess. incr. grad. by 1 tab wkly at
mthly intervals. Maint: 1 mg wkly. with
ranges from 0.25 mg-2 mg. Up to 4.5
mg wkly. have been used.
TABS: 2. Inhibit. lact: Admin. during 1st
day (24 hrs.) post-partum: 1 mg (2 x 0.5
mg tabs) as single dose.
Suppress. estab. lact: 0.25 mg (1/2 0.5 mg tab) every 12 hrs. for 2 days (1 mg total dose).
Tmt. of hyperprolactinemic disord.
Tmt. of dysfunct. assoc. with hyperprolactinem., include. amenorrhea, oligomenorrhea, anovulat. and galactorrhea.
Indic. in pts. with prolactin-secret. pituitary adenoma. (micro-and macroprolactinomas), idiopathic hyperprolactinem., or empty sella syndr.with assoc. hyperprolactinemia. Inhibit. and suppress. of lact.
C/I: Hypersens. to cabergoline or ergot alkaloid.
Hist. of pulmon., pericard. and retroperitoneal fibrotic disord.
Pts. with hep. insuffic. and with toxaemia of preg.
Co-admin. with anti-psychotics or admin. to women with a history of puerperal psychosis.
Admin. for long-term tmt. See lit.
Domapine Agonist. Quinagolide HCl 0.025, 0.05 mg. TABS: 3 + 3 x 25 μg, 50 μg (starter pack). 25 μg/day for first 3 days, foll. by 50 μg/day for 3 days. From day 7: 75 μg/day. See lit.
2nd line tmt. hyperprolactinem.
(idiotpath./due to prolactin secret. micro/
macroadenoma) and clin. maninfests.
(galactorrh., oligomenrrh., infertil.,
reduced libido).
Domapine Agonist. Quinagolide HCl 0.075, 0.15 mg. TABS: 3 + 3 x 25 μg, 50 μg (starter pack);
30 x 75 μg, 150 μg. 25 μg/day for first 3
days, foll. by 50 μg/day for 3 days. From
day 7: 75 μg/day. See lit.
2nd line tmt. hyperprolactinem.
(idiotpath./due to prolactin secret. micro/
macroadenoma) and clin. manifests.
(galactorrh., oligomenrrh., infertil.,
reduced libido).
Progestogen. Norethisterone Acetate 5 mg. TABS: 20. See lit.
Dysfunct. bleed., primary and second.
amenorrh., premenstrual syndr.,
mastopathy, uterine hypoplasia, timing of
menstruation, endometriosis.
C/I: Pregn., severe disturb. liver funct.,
Dubin-Johnson syndr., Rotor syndr.,
past, present liver tumors, history
jaundice, severe prurit., herpes during
pregn., thromboembol. processes
Progestogen. Medroxyprogesterone Acetate 5 mg. TABS.: 100, 24. Endometriosis: Oral MPA 10 mg three times per day for 90 consec. days, begin. on the 1ST d of the menstrual cycle.
Menopaus. Vasomotor Sympt.: Oral MPA 10-20 mg/d given continuous.
Diagn. of prim. and secon. Amenorrhea: Oral MPA 2.5-10 mg/d for 5-10 d.
Tmt. of second. Amenorrhea: Oral MPA 2.5- 10 mg dly. for 5-10 days, for 3 consecut. cycles. In pts. with hypotrophy of the endometrium, estrogens should be used concomit. with MPA ther.
Dysfunctional (Anovulatory) Uterine Bleed.: Oral MPA 2.5 to 10 mg/ d for 5–10 d for 2-3 cycles and then discont. to see if the dysfunct. has regressed. If bleed. occurs from a poorly proliferative endometrium, estrogens should be used concomit. with MPA ther.
Opposition of endometrial effects of estrogen in menopaus. women being treated with estrogen (Hormone Therapy [HT]): For women taking 0.625 mg of conjugated estrogen or an equivalent dly. dose of another estrogen, MPA can be given in one of two regimens:
Continuous regimen of MPA- Oral MPA 2.5 to 5.0 mg dly.
Sequent. regimen of MPA- Oral MPA 5 to 10 mg dly. for 10- 14 consecut. d. of a 28-d or monthly cycle.
Indicated for cases requiring progesterone supplem.
C/I: Hypersens. Known/suspect. preg. Known, past or suspect. breast cancer; Previous idiopathic or current venous thromboembolism (DVT, PE). Active/recent arterial thromboembolic dis. (e.g angina, MI); Acute liver dis., or a history of liver dis. as long as liver funct. tests have failed to return to normal. Porphyria.
